XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC ...Middle East

- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for...

Read More Details
Finally We wish PressBee provided you with enough information of ( XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC )

Also on site :

• Zuckerberg unveils new ‘superintelligence laboratory’
• Padres To Select Eduarniel Nunez
• Two Chinese nationals charged for trying to recruit spies in US military